TY - GEN
T1 - Anti-tumor effects of cavitation induced with phase-change nano droplet and ultrasound
AU - Kawabata, Ken Ichi
AU - Asami, Rei
AU - Azuma, Takashi
AU - Yoshikawa, Hideki
AU - Umemura, Shin Ichiro
PY - 2009
Y1 - 2009
N2 - We performed a study to look into the therapeutic application of a novel diagnostic and therapeutic agent, phase change nano droplet (PCND), in combination with 1-MHz ultrasound. It was found using gel phantoms that PCND works as a cavitation accelerator for a 1-MHz ultrasound only when an ultrasound which changes the phase of PCND from liquid to gas (phase change ultrasound) is exposed in advance. A nano droplet that cannot change its phase to a gas does not work even in the presence of the phase change ultrasound. The cavitation induction with the aid of a PCND was observable by B-mode echography as a brightness change. Such a brightness change was also observed in in vivo experiments on tumor baring mice in the presence of a PCND and a phase change ultrasound. Moreover, tissue damage was observed at the site of the brightness change. The lack of either a PCND or a phase change ultrasound did not induce any brightness change, suggesting the same mechanism as a gel phantom works in living tissues. Our results are promising for use in a noble ultrasound therapy system with high selectivity and safety while improving the throughput of current ultrasound tumor treatment systems.
AB - We performed a study to look into the therapeutic application of a novel diagnostic and therapeutic agent, phase change nano droplet (PCND), in combination with 1-MHz ultrasound. It was found using gel phantoms that PCND works as a cavitation accelerator for a 1-MHz ultrasound only when an ultrasound which changes the phase of PCND from liquid to gas (phase change ultrasound) is exposed in advance. A nano droplet that cannot change its phase to a gas does not work even in the presence of the phase change ultrasound. The cavitation induction with the aid of a PCND was observable by B-mode echography as a brightness change. Such a brightness change was also observed in in vivo experiments on tumor baring mice in the presence of a PCND and a phase change ultrasound. Moreover, tissue damage was observed at the site of the brightness change. The lack of either a PCND or a phase change ultrasound did not induce any brightness change, suggesting the same mechanism as a gel phantom works in living tissues. Our results are promising for use in a noble ultrasound therapy system with high selectivity and safety while improving the throughput of current ultrasound tumor treatment systems.
UR - http://www.scopus.com/inward/record.url?scp=77952862030&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952862030&partnerID=8YFLogxK
U2 - 10.1109/ULTSYM.2009.5441532
DO - 10.1109/ULTSYM.2009.5441532
M3 - Conference contribution
AN - SCOPUS:77952862030
SN - 9781424443895
T3 - Proceedings - IEEE Ultrasonics Symposium
SP - 208
EP - 211
BT - 2009 IEEE International Ultrasonics Symposium and Short Courses, IUS 2009
PB - Institute of Electrical and Electronics Engineers Inc.
T2 - 2009 IEEE International Ultrasonics Symposium, IUS 2009
Y2 - 20 September 2009 through 23 September 2009
ER -